PCSK9 and benign neoplasm: This study is the first to reveal an immune mechanism by which the liver modulates heart transplant rejection through the PCSK9/CD36 axis, expanding the understanding of PCSK9’s role in immunoregulation and offering a novel therapeutic target for preventing transplant rejection.